Markets

Aduro Biotech soars 100% on IPO

Aduro Biotech ( ADRO ) is the latest biotech IPO to soar on its public market debut, as the immunotherapy developer gained over 100% . Aduro boasts impressive backers, a large market opportunity and promising results from its Phase 2a trial for pancreatic cancer.

The last biotech to fly up that high was Spark Therapeutics ( ONCE ) in January, and the gene therapy company now trades over 230% above its offer price.

With a market cap of $1.2 billion, Aduro is the first billion-dollar health care company to double on its first day in over ten years . The next highest first-day pop for so large a health care company was Accuray's 58% gain on its IPO in 2007. Aduro is the largest of any IPO to pop 100% since Sprouts Farmers Market ( SFM ) in August 2013.

Billion-dollar biotechs have become more common recently: four have listed in the US in the past year, including Aduro, Cellectis ( CLLS ), FibroGen ( FGEN ) and Juno Therapeutics (JUNO). The largest of these - Juno - is held by the Renaissance IPO ETF . Unlike most biotechs, Aduro will have nearly $500 million in cash , thanks to the IPO and a $200 million upfront collaboration payment from Novartis. Both Novartis and Johnson & Johnson bought shares on the offering.

Six other biotechs have popped over 70% on the IPO since 2013. Two have dropped significantly, while the other four continued to soar ever higher. Gene therapies targeting rare diseases and cancer have been among the hottest stocks in the biotech space.

Aduro: The latest biotech IPO to pop
Company (Ticker) Business IPO market cap ($M) 1st-day Pop Return as of 4/15
Aduro Biotech ( ADRO ) Immunotherapy: pancreatic cancer $1,197 147% 147%
Dicerna Pharmaceuticals (DRNA) RNAi: rare liver disease, cancer $266 207% 23%
Spark Therapeutics ( ONCE ) Gene therapy: rare eye diseases $582 117% 229%
Ultragenyx Pharmaceutical (RARE) Rare genetic diseases $610 101% 200%
Agios Pharmaceuticals (AGIO) Cancer, rare genetic diseases $542 74% 451%
Kindred Biosciences (KIN) Pet pain and itching $105 71% 0%
Kite Pharma (KITE) Immunotherapy; cancer $733 71% 267%
The article Aduro Biotech soars 100% on IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

FGEN KDNY SFM CLLS

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More